An observational study in Essential Hypertension, sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2019-02-20.
Sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd (part of Menarini Group) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Essential Hypertension with a site in Korea, Republic of — 11 open to participants now, 13 under way, 4 of them phase 3. Essential Hypertension · Korea, Republic of.
Among the 99 studies in Essential Hypertension with a site in Korea, Republic of, this one is the 7th largest by enrollment of the 13 observational ones that give a count, is one of 5 that started in 2015, is one of 13 observational ones, and was the 44th registered.
481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.
Browse Essential Hypertension studies →11 of the 99 studies in Essential Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19+
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+
Shin Poong Pharmaceutical Co. Ltd. · Sites in Korea, Republic of
Ages 19–75
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 19 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,250 is above the median of 718 across 71 observational studies indexed under Essential Hypertension.
Median enrollment 190 across the 86 interventional studies, 3,250 across the 13 observational. Of the 78 that completed or were terminated, 7 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 99 have an industry lead sponsor. The 10 most frequent:
This study is registered under A.Menarini Asia-Pacific Holdings Pte Ltd, one of the names counted as Menarini Group. Under that name alone:
A.Menarini Asia-Pacific Holdings Pte Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.
Menarini Group has 1 study filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
3 of the studies in Essential Hypertension with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06220773Phase 3Boryung Pharmaceutical Co., LtdA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | 2026-12 |
| NCT07373613Boryung Pharmaceutical Co., LtdA Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension | 2027-02-01 |
| NCT06282549Yuhan CorporationStudy to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 99 studies in Essential Hypertension with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is:
To evaluate the effects of NEBILET®(Nebivolol), used as monotherapy or in combination with other antihypertensive agents, in the control of BP and in the metabolic profile of patients with essential hypertension (with or without co-morbidities) after 12 weeks and 24 weeks.
Nebivolol, the third-generation beta-blocker with vasodilatory effect, potentiates nitric oxide by activating the synthesis of nitric oxide of vascular endothelial cells and improves the function of vascular endothelial cells by reducing oxidation stress. The efficacy of NEBILET®(Nebivolol) has been demonstrated in randomized controlled trials not only as monotherapy but also as add-on therapy with angiotensin-converting-enzyme inhibitor, angiotensin II receptor blocker, diuretic and other anti-hypertensive agents in lowering the blood pressure.
Based on previous study results mentioned above, the present study aims to observe the effect of NEBILET®(Nebivolol) on controlling blood pressure and metabolic profile change in Korean patients with hypertension under routine clinical practice.
In addition, this study aims to identify additional benefits of NEBILET®(Nebivolol) administration in patients with essential hypertension under various treatment environments and existing co-morbidities in Korea, expected to provide detailed information about efficacy of blood pressure control, lipid and carbohydrate metabolism of NEBILET®(Nebivolol) administration in Korean patients with essential hypertension.
Male and female patients with essential hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In patient diagnosed with essential hypertension,
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mean change of the Systolic Blood Pressure and Diastolic Blood Pressure
Mean change of the Systolic Blood Pressure and Diastolic Blood Pressure after 12 weeks(±2 weeks) and 24 weeks (±2 weeks) compared to Baseline
Time frame: 24 weeks
Controlled patient rate in targeted Systolic Blood Pressure and Diastolic Blood Pressure range
Controlled patient rate in targeted Systolic Blood Pressure and Diastolic Blood Pressure range after 12 weeks (±2 weeks) and 24 weeks (±2 weeks) compared to Baseline
Time frame: 24 weeks
Change of glucose (HbA1c, fasting blood sugar), Na, K, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol
Change of glucose (HbA1c, fasting blood sugar), Na, K, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol at 12 weeks (±2 weeks) and 24 weeks (±2 weeks) compared to Baseline
Time frame: 24 weeks
Changes in Heart Rate and Heart Rate Variability after treatment with NEBILET® (Nebivolol) versus baseline values in patients receiving the concomitant antihypertensive therapies.
Changes in Heart Rate and Heart Rate Variability at 12 weeks (±2 weeks) and 24 weeks (±2 weeks) after treatment with NEBILET® (Nebivolol) versus baseline values in patients receiving the concomitant antihypertensive therapies.
Time frame: 24 weeks
Mean change of the Systolic Blood Pressure and Diastolic Blood Pressure compared to baseline depending on the treatment status and type of anti-hypertensive concomitant medication
Mean change of the Systolic Blood Pressure and Diastolic Blood Pressure after 12 weeks and 24 weeks compared to baseline depending on the treatment status and type of anti-hypertensive concomitant medication
Time frame: 24 weeks
Plan to share: No
Ran from Jul 2015 to primary completion in Mar 2017, 20 months.
Of 27 observational studies under Essential Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 52. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
A.Menarini Asia-Pacific Holdings Pte Ltd →